Latest Developments in Asia Pacific Endotoxin And Pyrogen Testing Market

back-icon

Back to Report

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Latest Developments in Asia Pacific Endotoxin And Pyrogen Testing Market

  • Medical Devices
  • Feb 2024
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

  • In May 2024, FUJIFILM Wako Pure Chemical Corporation expanded its pyrogen testing capabilities in Japan by launching a next-generation LAL reagent system designed to deliver faster and more accurate results. This development reflects the company’s ongoing commitment to enhancing pharmaceutical safety and streamlining quality control procedures across Asia-Pacific. The innovation supports growing biopharmaceutical production in the region and reinforces FUJIFILM Wako’s leadership in the endotoxin and pyrogen testing space
  • In March 2024, Lonza Group announced the expansion of its endotoxin testing solutions in Singapore, introducing automated cartridge-based technology for high-throughput pharmaceutical testing. This move is aimed at addressing rising demand for efficient contamination control in vaccine and biologics production in the region. The expansion aligns with Lonza’s strategic plan to serve growing APAC pharmaceutical manufacturing hubs
  • In February 2024, bioMérieux inaugurated a new quality control center in South Korea focusing on microbiological safety and pyrogen detection. The facility will provide advanced testing solutions and training to local pharmaceutical companies, reinforcing bioMérieux’s commitment to supporting regulatory compliance and public health in the region
  • In January 2024, Associates of Cape Cod, Inc. (ACC) entered into a distribution agreement with a major diagnostics provider in India to expand access to its endotoxin testing reagents and systems. This partnership is intended to improve pharmaceutical safety testing in emerging Indian biopharma markets and expand ACC’s footprint in South Asia
  • In December 2023, Thermo Fisher Scientific Inc. announced a strategic collaboration with a biopharmaceutical firm in Australia to co-develop rapid endotoxin detection platforms tailored to local regulatory and manufacturing needs. The collaboration enhances localized capabilities and reflects Thermo Fisher’s dedication to innovation and customer-centric solutions in the Asia-Pacific region